Difficulty: Medium
Average Score: 69%
Practice
Which of the following is not an attribute of amlodipine?
Correct answer
C
Rationale
The correct answer is C) Generation of an active metabolite. Amlodipine is a dihydropyridine calcium channel blocker that is primarily eliminated unchanged in the urine, with minimal hepatic metabolism. Therefore, it does not generate an active metabolite.
Option A) High and consistent oral bioavailability is true for amlodipine, as it is well-absorbed orally and shows consistent plasma concentrations. Option B) Large volume of distribution is also a characteristic of amlodipine, as it has a high distribution into tissues. Option D) Long elimination half-life is another attribute of amlodipine, as it has a prolonged half-life allowing for once-daily dosing.
Understanding the pharmacokinetic properties of cardiovascular drugs like amlodipine is crucial for healthcare professionals to make informed decisions regarding dosing, monitoring, and potential drug interactions. Knowing that amlodipine does not generate active metabolites helps in understanding its pharmacological profile and potential for drug-drug interactions compared to drugs that do undergo significant metabolism. This knowledge is essential for safe and effective pharmacotherapy in patients with cardiovascular conditions.
Option A) High and consistent oral bioavailability is true for amlodipine, as it is well-absorbed orally and shows consistent plasma concentrations. Option B) Large volume of distribution is also a characteristic of amlodipine, as it has a high distribution into tissues. Option D) Long elimination half-life is another attribute of amlodipine, as it has a prolonged half-life allowing for once-daily dosing.
Understanding the pharmacokinetic properties of cardiovascular drugs like amlodipine is crucial for healthcare professionals to make informed decisions regarding dosing, monitoring, and potential drug interactions. Knowing that amlodipine does not generate active metabolites helps in understanding its pharmacological profile and potential for drug-drug interactions compared to drugs that do undergo significant metabolism. This knowledge is essential for safe and effective pharmacotherapy in patients with cardiovascular conditions.